Nilotinib With Radiation for High Risk Chordoma

Inclusion Criteria: * Histologically confirmed chordoma * Considered to have high risk disease * Measurable disease * Life expectancy \> 3 months * Adequate organ function * Able to swallow oral capsules Exclusion Criteria: * Previous treatment with any other tyrosine kinase inhibitor * Previous treatment with radiotherapy to the primary or recurrent chordomas * Impaired cardiac function * Currently receiving treatment with strong CYP3A4 inhibitors * Requires anticoagulation with coumadin * Impaired GI function or GI disease that may significantly alter the absorption of study drug * Acute or chronic pancreatic disease * Known cytopathologically confirmed CNS infiltration * Another primary malignant disease which requires systemic treatment * Acute or chronic liver disease or severe renal disease considered unrelated to the cancer * History of significant congenital or acquired bleeding disorder unrelated to cancer * Major surgery within 4 weeks prior to Day 1 of the study or who have not recovered from prior surgery * Treatment with other investigational agents within 30 days of Day 1 * History of non-compliance to medical regimens * Pregnant or breast-feeding